Drug Trial Radar · NCT07263230
The Safety and Efficacy of Roflumilast Foam in HS
Last checked: Nov 20, 2026Latest source record: Jul 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Sep 1, 2026
Primary completion
Aug 2028
Study completion May 2029
Sponsor
- Lead sponsor
- Beth Israel Deaconess Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 4, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study investigates the efficacy of topical roflumilast foam in patients with HS.
Conditions
- Hidradenitis Suppurativa (HS)
Interventions
Roflumilast 0.3% topical foamDrug
Roflumilast foam, 0.3%, is a phosphodiesterase 4 inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change from Baseline in Abscess and Inflammatory Nodule (AN) Count at Week 16.Time frame: Baseline and Week 16
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beth Israel Deaconess Medical Center
Boston, Massachusetts · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.